Should we modify the principles of risk evaluation and recurrence preventive treatment of patients with calcium oxalate stone disease in view of the etiologic importance of calcium phosphate?

被引:0
作者
Hans-Göran Tiselius
机构
[1] Karolinska institutet,Divison of Urology, Department of Clinical Science, Intervention and Technology
来源
Urolithiasis | 2015年 / 43卷
关键词
Calcium oxalate; Calcium phosphate; Randall’s plaques; Loop of Henle; Tubular urine; Diurnal variation; Urine pH; AP(CaOx) index; AP(CaP) index; Risk periods; Potassium citrate; Vitamin E; Allopurinol; Thiazides; Furosemide;
D O I
暂无
中图分类号
学科分类号
摘要
Prevention of recurrent calcium oxalate (CaOx) stone formation in the urinary tract is important to avoid negative effects on renal function, patient suffering and to reduce health care cost. Present shortcomings in this regard can be explained both by insufficient understanding of the mechanisms of stone formation and by poor patient compliance to those regimens that nevertheless have proven effective. During the past years, we have got increased insights in the nature of CaOx stone formation and it is suggested that the improved understanding of this process can be used for a more dynamic risk evaluation and treatment regimen directed to specific risk periods that can be identified in the individual patients. Some of the possibilities with regard to the important role of calcium phosphate are discussed in this article.
引用
收藏
页码:47 / 57
页数:10
相关论文
共 211 条
[1]  
Robertson W(2006)Is prevention of stone recurrence financially worthwhile? Urol Res 34 157-161
[2]  
Straub M(2005)Diagnosis and metaphylaxis of stone disease. Consensus concept of the National Working Committee on stone disease for the upcoming German urolithiasis guideline World J Urol 23 309-323
[3]  
Strohmaier W(1991)Aspects on estimation of the risk of calcium oxalate crystallization in urine Urol Int 47 255-259
[4]  
Berg W(2002)Medical evaluation of nephrolithiasis Endocrinol Metab Clin North Am 31 1031-1050
[5]  
Beck B(2004)Recurrence prevention in patients with urinary tract stone disease Sci World J 31 417-425
[6]  
Hoppe B(2013)Kidney stones: an update on current pharmacological management and future directions Expert Opin Pharmacother 14 435-447
[7]  
Laube N(2003)Epidemiology and medical management of stone disease BJU Int 91 758-767
[8]  
Lahme S(2010)Improved cost-effectiveness and efficiency with a slower shockwave delivery rate BJU Int 105 692-696
[9]  
Schmidt M(2011)Ureteral stones: SWL treatment Arch Ital Urol Androl 83 10-13
[10]  
Hesse A(2000)Long-term follow-up of stone formers treated with a low dose of sodium potassium citrate Scand J Urol Nephrol 34 36-41